SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending amid widespread discussion and conflicting reports regarding a major deal with AI chip startup Groq, debated as either a $20 billion acquisition or a strategic licensing agreement. The community is sharply divided, with bulls touting it as a genius move to solidify NVIDIA's dominance in AI inference and talent acquisition, while bears decry it as a desperate, overpriced gambit. This strategic play aims to further cement NVIDIA's leadership across the entire AI hardware lifecycle, from training to the increasingly crucial inference market.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is a major trending topic as significant options expirations are driving notable short-term volatility and ongoing price debate. The community remains divided, with many bulls anticipating a strong breakout and long-term institutional accumulation once expiration pressure subsides, while bears highlight persistent selling pressure and perceived market manipulation.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending as community sentiment is fueled by technical indicators like anticipated "golden crosses" and calls for a significant breakout. Recent reports of users moving their coins to self-custody wallets due to security concerns and exchange transfer issues are also driving conversation. While many expect a rally for the "digital silver," others remain skeptical of its current performance.

Ethereum Classic

Ethereum Classic ($ETC) is trending amidst intense community debate, fueled by recent price volatility and its surprising appearance as a top trending asset. Many long-term holders express deep frustration over its sustained underperformance compared to other major cryptocurrencies, while a segment of the community remains strongly bullish, viewing current price levels as a significant discount and a "loading zone" before an anticipated breakout.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust ($SLV) is trending due to unprecedented industrial demand from AI data centers and clean energy, compounded by tightening global supply concerns following China's upcoming export restrictions and silver's inclusion on the US critical minerals list. The community is buzzing with talk of a historic "silver squeeze" and a significant re-rating of its value, with many anticipating triple-digit prices, while others warn of an overextended "parabolic" ascent and potential near-term pullback.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending following the significant FDA approval of YARTEMLEA, making it the first and only approved treatment for a life-threatening post-transplant complication in both adults and children. The community is actively discussing the drug's blockbuster potential due to its lack of competition and the company's validated pipeline, alongside hopes for a short squeeze and potential buyout speculation, particularly from existing partner Novo Nordisk. Excitement is building ahead of the upcoming conference call where further details, including pricing, are anticipated.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF ($BITO) is actively discussed for its attractive monthly dividends, which many investors are buying on dips to accumulate shares for long-term income and potential future Bitcoin appreciation. However, ongoing price volatility in Bitcoin and the ETF's price decay remain key community talking points, with some questioning if dividend payouts truly offset capital fluctuations.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is a major talking point after reports surfaced that a key industry player halted evaluation of its 18A chipmaking process, igniting furious debate among investors who largely perceive this as a manipulative "hit piece." Community sentiment is split, with many highlighting Intel's aggressive pricing strategies and bullish long-term outlook for its foundry advancements and government backing, urging others to "buy the dip" amidst perceived institutional pressure.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

The Defiance Daily Target 2X Long SMCI ETF ($SMCX) is trending amid strong bullish sentiment for its underlying asset, Super Micro Computer ($SMCI), driven by positive news like Nvidia's China chip shipments and significant AI infrastructure investments. Traders are actively debating its extreme volatility and decay concerns, with many viewing current price levels as a "buy the dip" opportunity for substantial gains as they anticipate an AI sector rally.

LendingClub Corp. engages in the operations of digital marketplace bank. It operates through the LendingClub Bank and LendingClub Corporation (Parent Only) segments. The LendingClub Bank segment involves the provision of full complement of financial products and solutions, loans, leases, and deposits. The LendingClub Corporation (Parent Only) segment includes the holding company legal entity. The company was founded by Renaud Laplanche and Soulaiman Htite in 2006 and is headquartered in San Francisco, CA.

LendingClub Corp

LendingClub is trending due to multiple recent analyst upgrades, including J.P. Morgan naming it a top fintech pick with raised price targets, alongside strong Q2 and Q3 earnings beats and a new $100 million share repurchase program. The community is buzzing about its strategic expansion into home improvement loans and high institutional ownership, though some debate its growth pace compared to peers. As the fintech sector eyes potential boosts from future rate cuts, many see LendingClub as an undervalued digital bank with solid fundamentals.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anavex Life Sciences' (AVXL) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Anavex Life Sciences in a research report on Friday...

Anavex Life Sciences (AVXL) Projected to Post Quarterly Earnings on Monday

Anavex Life Sciences (NASDAQ:AVXL) will be releasing its Q4 2025 earnings before the market opens on Monday, December 22. (View Earnings Report at...

<ul class="summary-bullets"><li>The company now intends to request a re-examination of the opinion which would be undertaken by a different set of reviewers that conduct a new examination.</li><li>Anavex submitted an application to the EMA for Blarcamesine in November 2024.</li></ul>Shares of Anavex Life Sciences Corp. (AVXL) fell 3% after hours on Friday after the company said that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a negative opinion on its application seeking approval for the drug Blarcamesine in treating Alzheimer’s disease.In November, Anavex <a href="https://stocktwits.com/news-articles/markets/equity/avxl-shares-slump-pre-market-after-ema-committee-fails-to-recommend-approval-for-alzheimers-drug/cLPQ7tkRE4E">said </a>it was informed by the CHMP of a negative trend vote on its application for Blarcamesine following its oral explanation in a session held behind closed doors on Nov. 11. The company was awaiting a formal opinion from the committee.<h2 class="st-heading-2">Negative Opinion ‘As Expected’</h2>Anavex <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-provides-update-on-regulatory-review-in-the-eu-for-blarcamesine-to-treat-early">said</a> on Friday that the CHMP has indeed adopted a negative opinion “as expected.” CHMP provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens chances for an EMA approval for the drug.The company now intends to request a re-examination of the opinion which would be undertaken by a different set of reviewers that conduct a new examination, independent from the first opinion.Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December. If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.Besides Alzheimer’s, Anavex is also studying Blarcamesine in treating Parkinson's disease dementia and Rett syndrome.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AVXL stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.A Stocktwits user opined that this is the best time for big pharma players “to throw bone for this company” provided the low share price and “promising assets.”&nbsp;<stembedurl>https://stocktwits.com/lookupdownside/message/639061239</stembedurl><a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is down 63% this year and by 52% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/oracle-denies-data-center-delay-report-after-shares-slide-on-openai-build-out-concerns/cLICt16RE8O">Oracle Denies Data Center Delay Report After Shares Slide On OpenAI Build-Out Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Anavex Stock Slides After Hours On EMA Panel’s Negative Alzheimer’s Drug Opinion — Retail Traders Talk Buyout Potential

Anavex said on Friday that the CHMP has indeed adopted a negative opinion “as expected.”

Equity

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (Anavex or the Company) (NASDAQ...

Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL)

Anavex Life Sciences (AVXL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Anavex Life Sciences' (AVXL) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued a "buy" rating and set a $24.00 price target on shares of Anavex Life Sciences in a research report on Wednesday...

Anavex Life Sciences (NASDAQ:AVXL) Posts Earnings Results, Beats Expectations By $0.02 EPS

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating...

<ul class="summary-bullets"><li>The company said its net loss for the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024.</li><li>The company is now seeking a re-examination of CHMP’s opinion on its Alzheimer’s drug, Blarcamesine.&nbsp;</li><li>It expects a cash runway of more than 3 years.</li></ul> Shares of Anavex Life Sciences Corp. (AVXL) jumped 10% on Monday afternoon after the company reported a lower-than-expected loss for the fourth quarter.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provides-business-upd">said</a> that net loss in the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024, and lower than the loss of $0.15 per share expected by analysts, according to data from Fiscal AI.The company ended the quarter with cash and cash equivalents of $102.6 million. It now expects a cash runway of more than 3 years.<h2 class="st-heading-2">Blarcamesine’s Path Forward</h2>Anavex is focused on developing treatments for neurodegenerative disorders like Alzheimer’s. “There are currently an estimated 7.2 million people living with Alzheimer’s disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally, targeted upstream medicines, particularly in the context of early Alzheimer’s disease,” said CEO Christopher U. Missling.Earlier this month, Anavex<a href="https://stocktwits.com/news-articles/markets/equity/avxl-shares-slump-pre-market-after-ema-committee-fails-to-recommend-approval-for-alzheimers-drug/cLPQ7tkRE4E"> said</a> that a European Medicines Agency (EMA) committee did not recommend approval of the company’s application for its Alzheimer’s drug, Blarcamesine. The Committee for Medicinal Products for Human Use provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens the chances of EMA approval for the drug.The committee is expected to adopt a formal opinion on the application at its December meeting, the company said, while adding that it intends to request a re-examination of the committee’s opinion. The firm reiterated the course of action on Tuesday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AVXL stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user opined that they are “cautiously optimistic” about the stock’s future.<stembedurl>https://stocktwits.com/Filldagap/message/637414773</stembedurl>AVXL stock is down 68% this year and by 63% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pmcb-stock-jumps-after-company-sells-stake-in-femasys/cL52o2lREgL">PMCB Stock Jumps 25% After Company Sells Stake In Femasys</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug

Anavex ended the quarter with cash and cash equivalents of $102.6 million.

A Preview Of Anavex Life Sciences's Earnings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Current Price	$3.72
Prev Close	$3.73
Open	$3.71
Dividend Yield	0.00%
50-Day Moving Average	$5.68
Beta	1.49
Avg. Volume	4.27M
PE Ratio	-6.84

52-Week High	$14.44
52-Week Low	$2.86
Market Capitalization	$332.37M
EPS (Annual)	-$0.5438
Price to Book	3.40
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

AVXL
Anavex Life Sciences Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AVXL News

AVXLAnavex Life Sciences Corp